Equities

Voyager Therapeutics Inc

Voyager Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.59
  • Today's Change0.16 / 2.95%
  • Shares traded27.38k
  • 1 Year change-18.75%
  • Beta0.8714
Data delayed at least 15 minutes, as of Nov 22 2024 14:57 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform5
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Voyager Therapeutics Inc have a median target of 18.00, with a high estimate of 30.00 and a low estimate of 7.00. The median estimate represents a 231.49% increase from the last price of 5.43.
High452.5%30.00
Med231.5%18.00
Low28.9%7.00

Earnings history & estimates in USD

On Nov 12, 2024, Voyager Therapeutics Inc reported 3rd quarter 2024 losses of -0.16 per share. This result exceeded the -0.45 consensus loss of the 10 analysts covering the company and exceeded last year's 3rd quarter results by 72.88%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+10.56%
Voyager Therapeutics Inc reported annual 2023 earnings of 2.97 per share on Feb 28, 2024.
Average growth rate+35.98%
More ▼

Revenue history & estimates in USD

Voyager Therapeutics, Inc. had 3rd quarter 2024 revenues of 24.63m. This bettered the 11.89m consensus of the 9 analysts covering the company. This was 83.63% below the prior year's 3rd quarter results.
Average growth rate+452.10%
Voyager Therapeutics, Inc. had revenues for the full year 2023 of 250.01m. This was 511.16% above the prior year's results.
Average growth rate+126.57%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.